Medicxi Ventures Management (Jersey) Ltd
In its 13F for Q3 2025 (holdings as of September 30, 2025, filed October 17, 2025), Medicxi Ventures Management (Jersey) Ltd reported 5 stock positions worth $744.4 million. Its top holding was Centessa Pharmaceuticals (CNTA) at 65.0% of the portfolio, followed by Phathom Pharmaceuticals (PHAT, 11.8%) and Newamsterdam Pharma (NAMS, 11.0%). Compared with Q2 2025, it opened 1 new position and sold out of 1. The biggest buy was a new position in Rapt Therapeutics and the biggest sale an exit from Rapt Therapeutics (RAPT).
- Most Recent 13F
- Q2 2026
- Location
- ST. HELIER, Y9
- CIK
- 0001715579
- Portfolio Value
- $744.4M (Q3 2025)
- SEC Filing
- 0001193125-25-242131 ↗ filed Oct 17, 2025
Holdings Value
Holdings 5 stocks · $744.4M
| CNTA Centessa Pharmaceuticals Ltd. | 65.03% | 19,963,157 | $484.1M | No change |
| PHAT Phathom Pharmaceuticals Inc. | 11.80% | 7,464,572 | $87.9M | No change |
| NAMS Newamsterdam Pharma Co. NV | 10.96% | 2,869,565 | $81.6M | No change |
| RAPT THERAPEUTICS INC | 9.68% | 2,794,000 | $72.1M | New |
| AURA Aura Biosciences Inc. | 2.52% | 3,039,892 | $18.8M | No change |
Portfolio Sells Q2 2025 → Q3 2025
| RAPT Rapt Therapeutics Inc. | Sold out | 0.00% | −5.23 |
Portfolio Buys Q2 2025 → Q3 2025
| RAPT THERAPEUTICS INC | New | 9.68% | +9.68 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 3 | $177.4M | PHAT, NAMS, AURA |
| Q1 2026 | 4 | $981.8M | CNTA, NAMS, PHAT, AURA |
| Q4 2025 | 5 | $835.0M | CNTA, PHAT, NAMS, RAPT THERAPEUTICS INC, AURA |
| Q3 2025 | 5 | $744.4M | CNTA, PHAT, NAMS, RAPT THERAPEUTICS INC, AURA |
| Q2 2025 | 5 | $427.3M | CNTA, PHAT, NAMS, RAPT, AURA |
| Q1 2025 | 5 | $437.7M | CNTA, NAMS, PHAT, RAPT THERAPEUTICS INC, AURA |
| Q4 2024 | 5 | $529.0M | CNTA, NAMS, PHAT, RAPT THERAPEUTICS INC, AURA |
| Q3 2024 | 4 | $528.9M | CNTA, PHAT, NAMS, AURA |
| Q2 2024 | 4 | $335.3M | CNTA, PHAT, NAMS, AURA |
| Q1 2024 | 5 | $449.2M | CNTA, PHAT, NAMS, MRUS, AURA |